Aberrant promoter hypermethylation of taxarotine induced gene 1 (TIG1) in head and neck cancer

Journal of Otolaryngology of Japan

Volumn 108, Issue 12, 2005, Pages 1152-1157

  Tokumaru, Yutaka ^a   Yahata, Yukiko ^a   Fujii, Masato ^a  

^a Hiratsuka City Hospital   (Japan)

Author keywords

Head and neck cancer; Hypermethylation; TIG1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; CYTOSINE DERIVATIVE; HYDROQUINONE; MOLECULAR MARKER; PROTEIN TIG1; TAZAROTENE; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CPG ISLAND; DIAGNOSTIC APPROACH ROUTE; DNA METHYLATION; GENE; GENE INACTIVATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; PROMOTER REGION; QUANTITATIVE ASSAY; REGULATORY MECHANISM; SEQUENCE ANALYSIS; TIG1 GENE; TUMOR DIAGNOSIS;

EID: 30344480483     PISSN: 00306622     EISSN: None     Source Type: Journal    
DOI: 10.3950/jibiinkoka.108.1152     Document Type: Article

References (22)

1. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 1999; 21: 163-167.
2. Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-3229.
3. Jing C, El-Ghany MA, Beesley C, Foster CS, Rudland PS, et al: Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. J Natl Cancer Inst 2002; 94: 482-490.
4. Tokumaru Y, Sun DI, Nomoto S, Yamashita K, Sidransky D: Re: Is TIG1 a new tumor suppressor in prostate cancer? J Natl Cancer Inst 2003; 95: 919-920.
5. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, et al: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686-692.
6. Harden SV, Tokumaru Y, Westra WH, Goodman S, Ahrendt SA, et al: Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 2003; 9: 1370-1375.
7. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
8. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, et al: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000; 28: E 32.
9. Usadel H, Brabender J, Danenberg KD, Jeronimo C, Harden S, et al: Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002; 62: 371-375.
10. Harden SV, Guo Z, Epstein JI, Sidransky D: Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol 2003; 169: 1138-1142.
11. Herman JG: Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol 1999; 9: 359-367.
12. Baylin SB, Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16: 168-174.
13. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, et al: Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000; 60: 892-895.
14. Zhou M, Tokumaru Y, Sidransky D, Epstein JI: Quantitative GSTP1 methylation levels correlate with Gleason grade and tumor volume in prostate needle biopsies. J Urol 2004; 171: 2195-2198.
15. Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI, et al: Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 2004; 10: 5518-5522.
16. Tokumaru Y, Nomoto S, Jeronimo C, Henrique R, Harden S, et al: Biallelic inactivation of the RIZ1 gene in human gastric cancer. Oncogene 2003; 22: 6954-6958.
17. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-107.
18. Gonzalez MV, Pello MF, Lopez-Larrea C, Suarez C, Menendez MJ, et al: Deletion and methylation of the tumour suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. J Clin Pathol 1997; 50: 509-512.
19. Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, et al: Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001; 61: 939-942.
20. Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI, et al: Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res 2003; 9: 3635-3640.
21. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, et al: Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005; 65: 1141-1145.
22. Sidransky D: Emerging molecular markers of cancer. Nat Rev Cancer 2002; 2: 210-219.